gene therapy sarepta - Search News

Order byBest matchMost fresh

Sarepta reports 2nd patient death

Second patient death reported with gene therapy for muscular dystrophy

Shares of Sarepta Therapeutics plunged Monday after the biotech drugmaker reported a second death in connection with its gene therapy for muscular dystrophy.

· 5h

Ticker: Second patient death reported with gene therapy for muscular dystrophy; Salmonella poisoning linked to pistachio cream

· 14h · on MSN

Sarepta Stock Plunges After Death of Second Patient Receiving Its Gene Therapy

· 1d

Sarepta reports second case of liver failure death after its gene therapy treatment

U.S. consumer prices rose slightly in May as gasoline prices remained subdued, but inflation is likely to pick up in the months as tariffs boost the cost of imported goods.

· 18h

Sarepta crashes after second death linked to Roche-partnered Elevidys

· 1d

Sarepta Therapeutics: Rebuilding The Thesis After Hitting Rock Bottom

19h

Sarepta Therapeutics Stock Plummets Over 40% On Second Fatal Case Linked To Its Gene Therapy

Sarepta suspends Elevidys use in non-ambulatory Duchenne patients after two liver failure deaths, triggering FDA review and clinical trial pause.

Managed Healthcare Executive15h

Sarepta Stops Shipments of Elevidys For Non-Ambulatory DMD Patients

A second patient with Duchenne muscular dystrophy has died from acute liver failure after receiving the gene therapy Elevidys.

STAT11h

After second Sarepta death, Duchenne muscular dystrophy community is racked by recrimination and worry

Another gene therapy death of a Duchenne patient has some parents and doctors criticizing the FDA's actions, even as other parents still push for the therapy.